default author photo

Tariq Ahmad

Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology

Exeter

United Kingdom

University of Exeter - IBD Pharmacogenetics Research Group

Barrack Road

Exeter, EX2 5DW

United Kingdom

SCHOLARLY PAPERS

4

DOWNLOADS

570

TOTAL CITATIONS

4

Scholarly Papers (4)

1.

COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or Vedolizumab

Number of pages: 35 Posted: 20 Dec 2021
Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, Imperial College Healthcare NHS Trust - Department of Medicine & Integrated Care, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Edinburgh - Centre for Inflammation Research, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Surgery and Cancer, Hull University Teaching Hospitals NHS Trust - Department of Gastroenterology, King’s College London - School of Immunology and Microbial Sciences, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, King's College Hospital - Department of Gastroenterology, University of Cambridge - NIHR BioResource, Cambridge University Hospitals NHS Trust - Department of Gastroenterology, University of Cambridge - NIHR BioResource, Barts Health NHS Trust - Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Immunology and Inflammation, Imperial College London, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, St Marks Hospital and Academic Institute - Department of Gastroenterology, University of Edinburgh - Centre for Inflammation Research, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction and affiliation not provided to SSRN
Downloads 276 (275,238)

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, Inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, ustekinumab, tofacitinib, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2

2.

Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study within the UK NIHR Inflammatory Bowel Disease Bioresource

Number of pages: 34 Posted: 07 Mar 2025
University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Wellcome Sanger Institute, University of Exeter - Royal Devon & Exeter Hospital, NHS Foundation Trust - Cambridge University Hospitals, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Queen Mary University of London, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, St Marks Hospital and Academic Institute, Government of the United Kingdom - Barts Health NHS Trust, Guy’s and St Thomas’ NHS Foundation Trust, Government of the United Kingdom - Royal Wolverhampton NHS Trust, Government of the United Kingdom - Royal Wolverhampton NHS Trust, Northern Care Alliance NHS Group, St Marks Hospital and Academic Institute, Government of the United Kingdom - Hull University Teaching Hospitals NHS Trust, National Institute for Health and Care Research IBD BioResource for Translational Research, Government of the United Kingdom - Department of Gastroenterology, Government of the United Kingdom - Leeds Teaching Hospitals, Guy’s and St. Thomas NHS Foundation Trust - Department of Gastroenterology, Wellcome Sanger Institute, Torbay and South Devon NHS Foundation Trust, Bristol Genetics Laboratory, University of Exeter, University of Exeter, NHS Foundation Trust - Cambridge University Hospitals, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group and Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology
Downloads 120 (604,538)

Abstract:

Loading...

Inflammatory bowel disease, NUDT15, nudix hydrolase 15, TPMT, thiopurine methyltransferase, myelosuppression, thiopurine, azathioprine, mercaptopurine, pharmacogenetics, loop-mediated isothermal amplification, cost effectivness

3.

Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)

Number of pages: 40 Posted: 21 Sep 2022
Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Institute of Biomedical and Clinical Science, Newcastle University, Government of the United Kingdom - Department of Gastroenterology, Barts Health NHS Trust - Department of Gastroenterology, NHS Lothian - Department of Gastroenterology, Imperial College London - Department of Immunology and Inflammation, St Marks Hospital and Academic Institute - Department of Gastroenterology, Imperial College London, Imperial College London - Department of Infectious Disease, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology and Imperial College London - Department of Metabolism, Digestion and Reproduction
Downloads 112 (630,858)

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, mRNA1273, breakthrough infection, Omicron, BA.4/5

4.

COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine Dose

Number of pages: 37 Posted: 25 Jul 2022
Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, Imperial College Healthcare NHS Trust - Department of Medicine & Integrated Care, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Edinburgh - Centre for Inflammation Research, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Surgery and Cancer, Government of the United Kingdom - Department of Gastroenterology, Guy’s and St. Thomas NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, King's College Hospital - Department of Gastroenterology, University of Cambridge - NIHR BioResource, University of Cambridge - NIHR BioResource, Barts Health NHS Trust - Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Immunology and Inflammation, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, St Marks Hospital and Academic Institute - Department of Gastroenterology, NHS Lothian - Department of Gastroenterology, Imperial College London, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction and Independent
Downloads 62 (942,565)
Citation 4

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, ustekinumab, tofacitinib, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, mRNA1273